{"id":245183,"date":"2026-10-10T09:31:37","date_gmt":"2026-10-10T14:31:37","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/10\/advances-in-systemic-treatment-of-breast-cancer"},"modified":"2026-10-10T09:31:37","modified_gmt":"2026-10-10T14:31:37","slug":"advances-in-systemic-treatment-of-breast-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/10\/advances-in-systemic-treatment-of-breast-cancer","title":{"rendered":"Advances in Systemic Treatment of Breast Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/advances-in-systemic-treatment-of-breast-cancer2.jpg\"><\/a><\/p>\n<p>Systemic therapy for breast cancer has evolved rapidly since 2020, driven by the expansion of targeted therapies, antibody\u2013drug conjugates, and immunotherapy across biologic subtypes. The integration of tumor molecular profiling and germline testing has enabled increasingly personalized, biomarker-guided treatment strategies. In hormone-receptor\u2013positive, human epidermal growth factor receptor 2 (HER2)\u2013negative disease, cyclin-dependent kinase 4 and 6 inhibitors remain foundational, whereas phosphatidylinositol 3-kinase pathway inhibitors, oral selective estrogen-receptor degraders, and antibody\u2013drug conjugates have transformed disease management after endocrine resistance. In HER2-positive disease, antibody\u2013drug conjugates \u2014 particularly trastuzumab deruxtecan \u2014 have improved outcomes and are being used in earlier lines of therapy, a development that is reshaping treatment paradigms.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Systemic therapy for breast cancer has evolved rapidly since 2020, driven by the expansion of targeted therapies, antibody\u2013drug conjugates, and immunotherapy across biologic subtypes. The integration of tumor molecular profiling and germline testing has enabled increasingly personalized, biomarker-guided treatment strategies. In hormone-receptor\u2013positive, human epidermal growth factor receptor 2 (HER2)\u2013negative disease, cyclin-dependent kinase 4 and 6 [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-245183","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=245183"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245183\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=245183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=245183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=245183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}